Executive Overview
For 32-year-old Becca Barnes, the ticking of the clock is not merely a metaphor for the passage of time; it is a stark, unyielding countdown. Diagnosed with Friedreich Ataxia (FA)—a rare, degenerative, and ultimately life-limiting genetic condition—Becca is facing the most formidable battle of her life. Having already endured the devastating loss of her two brothers to the very same illness, she is now confronting her own mortality with a singular, agonizing focus: securing enough time to watch her three young children grow up.
The urgency of Becca’s fight has been amplified by the rapid onset of her symptoms. Having kept her diagnosis private for nearly a decade, she can no longer ignore the physical reality of the disease as it compromises her mobility, balance, and independence. Yet, her struggle extends far beyond personal survival. It exposes a glaring chasm in modern British healthcare: the availability of a potentially life-altering medication that remains frustratingly out of reach.
While a groundbreaking drug known as omaveloxolone has gained regulatory approval in the United States and parts of Europe, it is currently unavailable on the UK’s National Health Service (NHS). Procuring the treatment privately carries a staggering price tag of £250,000 per year—an insurmountable sum for an ordinary working mother.
Becca’s story is more than a personal tragedy; it is an urgent investigative lens focused on the systemic barriers facing rare disease sufferers in the UK. Through a GoFundMe campaign and a national petition, she is fighting not only for her own future, but to ensure that future generations do not have to watch their loved ones slip away while a viable treatment sits just beyond the horizon.
Detailed Chronology: A Family’s Devastating History with Friedreich Ataxia
To understand the weight of Becca Barnes’s current battle, one must look back at the devastating shadow that Friedreich Ataxia has cast over her family for more than a decade. The tragedy began unfolding in 2009, long before Becca fully comprehended the insidious nature of the genetic disorder she carried.
The Loss of Two Brothers
In 2009, Becca was a teenager when her 19-year-old brother succumbed to the genetic condition. At the time, medical understanding of Friedreich Ataxia was significantly less advanced than it is today, and families navigating the diagnosis were often left in the dark, struggling to find reliable information or specialized care.
Medical professionals assured the family that the condition was statistically more prevalent in males and that the odds of multiple siblings inheriting the autosomal recessive disorder were remarkably low. They were incorrectly advised that neither Becca nor her sister were at significant risk of developing the disease.
Five years later, in 2014, the family suffered a second catastrophic blow. Becca’s eldest brother, Chris, passed away at the age of 29 after a long and grueling battle with the exact same disease. The sequential loss of two siblings in their youth left an indelible emotional scar on the family, instilling a profound, lingering anxiety about the genetic lottery that dictated their lives.
Discovery and Denial
Following Chris’s death, a grieving Becca began conducting her own exhaustive research into Friedreich Ataxia. It was during this investigative process that she uncovered the stark genetic realities of the condition: because both parents must carry the defective gene for a child to inherit the disorder, any subsequent offspring face a 25 percent chance of developing the disease.
Driven by a need to understand her own health status, Becca underwent genetic testing. The results brought devastating confirmation: she, too, carried the Friedreich Ataxia gene.
For nearly ten years, Becca chose to keep her diagnosis deeply private. In the psychological defense mechanism common to those facing terminal or degenerative illnesses, she pushed the reality to the back of her mind, refusing to fully accept a fate that had not yet manifested physically.
The Onset of Symptoms
However, biology cannot be negotiated away. As Becca approached her early thirties, the dormant condition began to awaken. Subtle lapses in balance evolved into noticeable difficulties with walking, coordination, and fatigue. The psychological weight of denial gave way to the undeniable physical truth of her diagnosis.
"You always think you’ve got time, I’m showing more symptoms and I’m thinking ‘wow, it’s actually real,’" Becca shared in an interview with the Manchester Evening News.
Today, the physical manifestations of Friedreich Ataxia disrupt her daily existence. Simple tasks that most individuals perform without a second thought—such as walking to the local shop to buy a bottle of milk—have become calculated logistical challenges. Furthermore, the loss of motor control has introduced social anxieties, forcing her to navigate public spaces where unsteady movements are frequently misconstrued by onlookers as public intoxication.
Supporting Context & Metrics: Understanding Friedreich Ataxia and the Access Gap
To fully grasp the magnitude of Becca’s campaign, it is essential to examine the clinical nature of Friedreich Ataxia, the mechanics of the treatment she seeks, and the economic and regulatory barriers that define modern healthcare access in the UK.
Clinical Profile of Friedreich Ataxia (FA)
Friedreich Ataxia is a rare, inherited, degenerative neurodegenerative disorder. It is caused by a mutation in the FXN gene, which encodes the mitochondrial protein frataxin. A deficiency in frataxin leads to the accumulation of iron within mitochondria, causing cellular damage and oxidative stress.
The primary systems affected include:
- The Spinal Cord: Resulting in the degeneration of nerve fibers and sensory pathways.
- Peripheral Nerves: Leading to a loss of sensation, particularly in the extremities.
- The Cerebellum: The region of the brain responsible for motor control and balance, leading to ataxia (loss of full control of bodily movements).
Key Clinical Symptoms:
- Progressive muscle weakness and loss of coordination (ataxia)
- Dysarthria (slurred or slow speech)
- Vision and hearing impairment
- Cardiomyopathy (heart muscle disease, which is often the primary cause of mortality)
- Scoliosis (curvature of the spine)
- Chronic, debilitating fatigue
The average life expectancy for individuals diagnosed with classical Friedreich Ataxia is historically restricted to the mid-30s to early 40s, typically curtailed by cardiac complications or severe neurological decline. With Becca about to turn 33, she is acutely aware that she is entering the critical window defined by these grim statistical averages.
The Treatment Landscape: Omaveloxolone
For decades, the medical management of Friedreich Ataxia was strictly palliative, focusing on physical therapy, management of cardiac symptoms, and assistive devices to maintain mobility. There were no disease-modifying therapies available to alter the underlying progression of neurological damage.
This paradigm shifted with the development of omaveloxolone (marketed as Skyclaris), an oral medication designed to activate the Nrf2 pathway, which restores mitochondrial function, reduces oxidative stress, and protects cells from degeneration.
- Global Approval Status: Omaveloxolone received regulatory approval from the United States Food and Drug Administration (FDA) in 2023 and has subsequently been greenlit by regulatory bodies in parts of Europe.
- UK Access and the NHS: Despite its international availability, the drug has faced hurdles in securing a recommendation from the National Institute for Health and Care Excellence (NICE) for routine commissioning within the NHS. Consequently, it remains unavailable through standard public healthcare pathways in the UK.
- The Private Care Barrier: For patients determined to access the drug independently, private healthcare providers quote costs of approximately £250,000 per year. For a working mother of three, this financial barrier is utterly insurmountable without philanthropic intervention.
Official Statements and Personal Appeals
Becca Barnes’s campaign is rooted not in anger at the medical system, but in a profound, maternal desperation to secure more shared years with her family. Her public appeals highlight the stark contrast between bureaucratic delay and human urgency.
Speaking about her motivations, Becca explained:
"The average life expectancy is only into the mid-30s. I’m about to turn 33. I’m just a mum with 3 children, I don’t want anything special. I just want to be here. I want to watch them grow up and I want to be able to take them places, make memories with them and just be with them."
Reflecting on the painful evolution of medical awareness surrounding the condition since her brothers’ diagnoses, she noted the bittersweet nature of modern advocacy:
"Now, it’s a lot more known, but it’s bittersweet, I’ve got it myself so I need it, I need the awareness, I need the medication. It’s just sad that it wasn’t an option for my brothers."
Crucially, Becca remains realistic about the limits of modern pharmacology, emphasizing that she is seeking time rather than a medical miracle:
"We’re not asking for a miracle, it isn’t a cure, it’s not going to make me what I was like five years ago. But I’m not asking for much, I’m just asking to be here."
Despite the physical and emotional toll of her diagnosis, Becca continues to work and maintain a sense of normalcy for her children, demonstrating extraordinary resilience:
"I do everything I can to keep myself as well as possible. I work, I try to carry on as normal and I refuse to let this condition completely take over my life."
Future Outlook: The Fight for Reform and Public Mobilization
Becca’s journey points toward a broader, systemic question regarding how rare diseases are prioritized within national healthcare budgets. As medical science advances, producing targeted, disease-modifying therapies for rare genetic conditions, health systems worldwide are increasingly strained by the high cost of orphan drugs.
The Path Forward: Petitions and Philanthropy
To bridge the gap between international approval and domestic NHS availability, patient advocates like Becca are turning to two primary mechanisms:
- Direct Fundraising: Through her GoFundMe campaign, Becca is attempting to raise the vital capital required to self-fund private access to omaveloxolone, buying precious time while institutional frameworks slowly evolve.
- Legislative Advocacy: Alongside her personal fundraising, Becca is actively promoting a parliamentary petition calling on the UK government and health authorities to review the accessibility of life-prolonging treatments for rare conditions like Friedreich Ataxia on the NHS.
The Broader Implications for NHS Policy
The debate surrounding omaveloxolone forces a difficult ethical and economic reckoning for the NHS. As precision medicines target smaller cohorts of patients with rare disorders, traditional cost-effectiveness thresholds established by bodies like NICE often struggle to accommodate the profound, life-extending value these therapies offer to individuals and their families.
For Becca Barnes, however, health economics are secondary to human realities. Her fight is a race against time—a mother utilizing every available platform to ensure that bureaucratic delays do not rob her children of the one thing they need most: their mother’s presence.
To support Becca Barnes in her fight, donations can be made directly to her GoFundMe fundraiser, and supporters can sign the official parliamentary petition here.
